BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is spotlighted in a recent episode of the “Test. Optimize. Scale.” podcast series, which features industry leaders and pioneers sharing insights and experiences of growing their businesses to scale. BiondVax CEO Amir Reichman is a guest of the popular on-demand podcast, which is hosted by Jason Fishman, SVP Digital Strategy for Digital Niche Agency. During the podcast, Reichman talked about his journey leading up to joining BiondVax in 2021 as well as the company’s current plans, which include developing a derisked pipeline of diversified and commercially viable products and platforms, including an innovative nanosized antibody (“NanoAb”) pipeline licensed from the Max Planck Society. “[BiondVax] had a company with a super team that knew how to develop drugs from zero to 100 and manage budget,” said BiondVax CEO Amir Reichman during the podcast. “They had massive labs and facilities. . . . However, they had $2.5 million in the bank and the IP [for its universal influenza vaccine] had basically flopped [in a phase 3 trial]. . . .It was an excellent opportunity. . . to in-license a new technology to the company. It becomes a new company in a very early stage, but with a massive edge over others. The team is super experienced in running trials. . . the capacity and capabilities are there. If we raise enough money with a nice business plan, we can in-license a technology and have a good start.”
To listen to the full interview, visit https://ibn.fm/YHtWc
To view the full press release, visit https://ibn.fm/8ihfh
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its prior vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.